Kenta Biotech
Zug, Zug, Switzerland
About Kenta Biotech
Kenta Biotech is focusing on the discovery and development of innovative, fully human monoclonal antibodies for the life-saving treatment of patients with serious infectious diseases. For the discovery of their monoclonal antibodies, they are using their proprietary MabIgX technology platform that enables the generation of an advanced class of fully human monoclonal antibodies that are expected to have superior safety and efficacy profiles.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $10.1M
- Funding stage: Early Stage Venture
- Last round: Series B (Mar 2009)
- Website: kentabiotech.com
- Phone: +41 5-8680-5252
Industries & Categories
Biotechnology, Medical
Social Profiles
Canonical: https://fsome.com/organization/kenta-biotech-2504587 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.